HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer

Author： Ziogas Dimosthenis  

Publisher： Springer Publishing Company

ISSN： 1068-9265

Source： Annals of Surgical Oncology, Vol.15, Iss.12, 2008-12, pp. : 3614-3615

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 217-221

Adis International

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

By Lidgren Mathias   Wilking Nils   Jonsson Bengt   Rehnberg Clas  

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1018-1028

Informa Healthcare

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer

By Sorscher Steven M.  

Cancer Investigation, Vol. 29, Iss. 7, 2011-07 ,pp. : 456-459

Informa Healthcare

Access to resources Recommend Favorite